Literature DB >> 16917939

Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism.

S Jill James1, Stepan Melnyk, Stefanie Jernigan, Mario A Cleves, Charles H Halsted, Donna H Wong, Paul Cutler, Kenneth Bock, Marvin Boris, J Jeffrey Bradstreet, Sidney M Baker, David W Gaylor.   

Abstract

Autism is a behaviorally defined neurodevelopmental disorder usually diagnosed in early childhood that is characterized by impairment in reciprocal communication and speech, repetitive behaviors, and social withdrawal. Although both genetic and environmental factors are thought to be involved, none have been reproducibly identified. The metabolic phenotype of an individual reflects the influence of endogenous and exogenous factors on genotype. As such, it provides a window through which the interactive impact of genes and environment may be viewed and relevant susceptibility factors identified. Although abnormal methionine metabolism has been associated with other neurologic disorders, these pathways and related polymorphisms have not been evaluated in autistic children. Plasma levels of metabolites in methionine transmethylation and transsulfuration pathways were measured in 80 autistic and 73 control children. In addition, common polymorphic variants known to modulate these metabolic pathways were evaluated in 360 autistic children and 205 controls. The metabolic results indicated that plasma methionine and the ratio of S-adenosylmethionine (SAM) to S-adenosylhomocysteine (SAH), an indicator of methylation capacity, were significantly decreased in the autistic children relative to age-matched controls. In addition, plasma levels of cysteine, glutathione, and the ratio of reduced to oxidized glutathione, an indication of antioxidant capacity and redox homeostasis, were significantly decreased. Differences in allele frequency and/or significant gene-gene interactions were found for relevant genes encoding the reduced folate carrier (RFC 80G > A), transcobalamin II (TCN2 776G > C), catechol-O-methyltransferase (COMT 472G > A), methylenetetrahydrofolate reductase (MTHFR 677C > T and 1298A > C), and glutathione-S-transferase (GST M1). We propose that an increased vulnerability to oxidative stress (endogenous or environmental) may contribute to the development and clinical manifestations of autism. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16917939      PMCID: PMC2610366          DOI: 10.1002/ajmg.b.30366

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  81 in total

Review 1.  Review: The role of glutathione in the regulation of apoptosis.

Authors:  A G Hall
Journal:  Eur J Clin Invest       Date:  1999-03       Impact factor: 4.686

Review 2.  GSTM1, GSTT1, and the risk of squamous cell carcinoma of the head and neck: a mini-HuGE review.

Authors:  S A Geisler; A F Olshan
Journal:  Am J Epidemiol       Date:  2001-07-15       Impact factor: 4.897

3.  The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism.

Authors:  C Lord; S Risi; L Lambrecht; E H Cook; B L Leventhal; P C DiLavore; A Pickles; M Rutter
Journal:  J Autism Dev Disord       Date:  2000-06

Review 4.  Receptor-mediated endocytosis of cobalamin (vitamin B12).

Authors:  B Seetharam
Journal:  Annu Rev Nutr       Date:  1999       Impact factor: 11.848

5.  Reduced vitamin B12 binding by transcobalamin II increases the risk of neural tube defects.

Authors:  L A Afman; N M Van Der Put; C M Thomas; J M Trijbels; H J Blom
Journal:  QJM       Date:  2001-03

6.  Effect of catechol-O-methyltransferase val158met genotype on attentional control.

Authors:  Giuseppe Blasi; Venkata S Mattay; Alessandro Bertolino; Brita Elvevåg; Joseph H Callicott; Saumitra Das; Bhaskar S Kolachana; Michael F Egan; Terry E Goldberg; Daniel R Weinberger
Journal:  J Neurosci       Date:  2005-05-18       Impact factor: 6.167

7.  Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation.

Authors:  P Yi; S Melnyk; M Pogribna; I P Pogribny; R J Hine; S J James
Journal:  J Biol Chem       Date:  2000-09-22       Impact factor: 5.157

8.  The neurological syndrome of infantile cobalamin deficiency: developmental regression and involuntary movements.

Authors:  P J Grattan-Smith; B Wilcken; P G Procopis; G A Wise
Journal:  Mov Disord       Date:  1997-01       Impact factor: 10.338

9.  Transcobalamin II 775G>C polymorphism and indices of vitamin B12 status in healthy older adults.

Authors:  Joshua W Miller; Marisa I Ramos; Marjorie G Garrod; Margaret A Flynn; Ralph Green
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

Review 10.  Identifying neurocognitive phenotypes in autism.

Authors:  Helen Tager-Flusberg; Robert M Joseph
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2003-02-28       Impact factor: 6.237

View more
  179 in total

1.  Glutamate carboxypeptidase II and folate deficiencies result in reciprocal protection against cognitive and social deficits in mice: implications for neurodevelopmental disorders.

Authors:  Laura R Schaevitz; Jonathan D Picker; Jasmine Rana; Nancy H Kolodny; Barry Shane; Joanne E Berger-Sweeney; Joseph T Coyle
Journal:  Dev Neurobiol       Date:  2012-06       Impact factor: 3.964

2.  Metabolic imbalance associated with methylation dysregulation and oxidative damage in children with autism.

Authors:  Stepan Melnyk; George J Fuchs; Eldon Schulz; Maya Lopez; Stephen G Kahler; Jill J Fussell; Jayne Bellando; Oleksandra Pavliv; Shannon Rose; Lisa Seidel; David W Gaylor; S Jill James
Journal:  J Autism Dev Disord       Date:  2012-03

3.  Autism, imprinting and epigenetic disorders: a metabolic syndrome linked to anomalies in homocysteine recycling starting in early life??

Authors:  Yves Ménézo; Pierre Mares; Marc Cohen; Michel Brack; Stephane Viville; Kay Elder
Journal:  J Assist Reprod Genet       Date:  2011-12       Impact factor: 3.412

4.  Maternal periconceptional folic acid intake and risk of autism spectrum disorders and developmental delay in the CHARGE (CHildhood Autism Risks from Genetics and Environment) case-control study.

Authors:  Rebecca J Schmidt; Daniel J Tancredi; Sally Ozonoff; Robin L Hansen; Jaana Hartiala; Hooman Allayee; Linda C Schmidt; Flora Tassone; Irva Hertz-Picciotto
Journal:  Am J Clin Nutr       Date:  2012-05-30       Impact factor: 7.045

Review 5.  Complementary and alternative medicine in autism: an evidence-based approach to negotiating safe and efficacious interventions with families.

Authors:  R Scott Akins; Kathy Angkustsiri; Robin L Hansen
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 6.  Mitochondrial dysfunction can connect the diverse medical symptoms associated with autism spectrum disorders.

Authors:  Richard E Frye; Daniel A Rossignol
Journal:  Pediatr Res       Date:  2011-05       Impact factor: 3.756

Review 7.  Autism: Is there a folate connection?

Authors:  R J Leeming; M Lucock
Journal:  J Inherit Metab Dis       Date:  2009-03-16       Impact factor: 4.982

8.  Mathematical modeling of the methionine cycle and transsulfuration pathway in individuals with autism spectrum disorder.

Authors:  Troy Vargason; Daniel P Howsmon; Stepan Melnyk; S Jill James; Juergen Hahn
Journal:  J Theor Biol       Date:  2016-12-29       Impact factor: 2.691

9.  Neuroligin-deficient mutants of C. elegans have sensory processing deficits and are hypersensitive to oxidative stress and mercury toxicity.

Authors:  Jerrod W Hunter; Gregory P Mullen; John R McManus; Jessica M Heatherly; Angie Duke; James B Rand
Journal:  Dis Model Mech       Date:  2010-01-18       Impact factor: 5.758

Review 10.  Association of methylenetetrahydrofolate reductase (MTHFR) gene C677T polymorphism with autism: evidence of genetic susceptibility.

Authors:  Vandana Rai
Journal:  Metab Brain Dis       Date:  2016-03-08       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.